3OCT

WHO: 2,000 Congolese workers get Ervebo

3 min read

13:42UTC

About 2,000 frontline workers in DR Congo had received Ervebo, a vaccine licensed against a different Ebola species, by 10 September; the Bundibugyo trial had not begun.

← Back to River boat carries Ebola 1,000 km downriver Jump to analysis ↓

ScienceDeveloping

Key takeaway

Ervebo's Bundibugyo trial is set to open in Ituri while new cases move to North Kivu.

About 2,000 frontline workers in DR Congo had received Ervebo by 10 September, the World Health Organization (WHO) said, from the 70,000 doses released in August⁠¹. Ervebo, made by Merck, is licensed against the Zaire species of Ebola, which caused the 2014-2016 West African epidemic. It is not licensed against Bundibugyo ebolavirus, the species driving this outbreak.

The Phase 3 trial of 20,000 doses against Bundibugyo, the large study that tests whether a vaccine protects, had not begun; WHO expected a start in October or November. The trial uses ring vaccination, immunising the contacts of each new case and their contacts in turn, so it needs fresh cases to measure anything.

With no licensed Bundibugyo vaccine, that trial is the more rigorous of two tests in this outbreak of whether any vaccine protects against it. The other, BRAVO, an MSF study that vaccinates about 20,000 frontline workers in Ituri and North Kivu and follows them for nine to 12 months, began in Bunia on 19 September. WHO said in September that it will begin in Ituri, where cases peaked in mid-August and have declined since. More of the new infections now arise around Butembo in North Kivu, so a trial placed where cases are thinning will collect its answer more slowly.

Deep Analysis

In plain English

Ervebo is a vaccine made for a different type of Ebola, called Zaire, which caused the huge West African outbreak a decade ago. Nobody knows yet if it protects against the Bundibugyo type now spreading in DR Congo. WHO has given it to about 2,000 health workers, just in case. It also plans a proper test, a 'ring' trial, in which the contacts of each new patient are vaccinated to see if fewer of them fall ill. That test only works if there are enough new cases. It is planned for Ituri, the province where cases are now falling.

Deep Analysis

Root Causes

Ervebo exists because the Zaire species caused repeated large outbreaks, giving companies and funders a reason to finish a vaccine. Bundibugyo has caused only a handful of outbreaks since its discovery in Uganda in 2007, so no species-matched product reached licensing.

Ring trials depend on incidence. A trial set up after a province's peak, as in Ituri, recruits slowly because each ring needs a fresh confirmed case.

Cold-chain logistics add delay. Ervebo must be stored frozen at very low temperatures, so every new trial site needs ultra-cold storage set up before the first ring can be vaccinated.

What could happen next?

Risk
An Ituri-only trial could end without an efficacy answer if incidence there keeps falling, as Sierra Leone's 2015 trial did.
Medium term · Suggested
Opportunity
Moving trial sites to Butembo would put the rings where new cases now are.
Short term · Suggested
Consequence
With 48,000 frontline doses still unused on 10 September, the bottleneck is delivery and uptake, not supply.
Immediate · Assessed

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: Guinea's 'Ebola ça suffit' ring trial began in April 2015 and showed Ervebo's forerunner protected against the Zaire species, though the West African epidemic was already waning. It worked because Guinea still had steady clusters of new cases in the trial's zones.

Counter-parallel: Sierra Leone's STRIVE trial, launched in 2015, vaccinated health workers but could not measure efficacy because cases fell too fast. It ended as a safety study, which is the outcome an Ituri-only trial risks.

The 70,000 doses came through the International Coordinating Group's Ebola stockpile, so DR Congo did not buy them. A trial result showing cross-protection would turn that existing stockpile into a Bundibugyo tool overnight.

A negative result would leave the outbreak dependent on species-matched candidates still in Phase 1, such as Moderna's mRNA-1469, whose path to large-scale supply is measured in years.

Consensus view: WHO's position, reported by Healio on 10 September, is that a trial is needed to learn whether Ervebo protects against Bundibugyo, and that results 'may take months'. Using 50,000 doses on frontline workers in the meantime is a hedge: if cross-protection exists, those most exposed get it first.

Counter-view: A medRxiv protocol paper (2026.07.09.26357654) modelling Bundibugyo vaccination compares ring designs with wider community campaigns, and the trade-off it sets out cuts against waiting. A ring needs new cases near each enrolled contact, and Ituri's incidence has fallen since mid-August.

Key tension: Whether the trial follows the virus to North Kivu, where it can measure protection, or stays in Ituri, where it was planned and where cases are drying up.

Sources:Healio

Mentions:Guinea →Ervebo →World Health Organization →Ituri Province →Bundibugyo ebolavirus →DR Congo →Zaire ebolavirus →International Coordinating Group on Vaccine Provision →Merck & Co. →Sierra Leone →North Kivu →Phase 3 →Butembo →Ebola →Healio →STRIVE trial →

First Reported In

Update #14 · River boat carries Ebola 1,000 km downriver

Healio· 3 Oct 2026

Read original →

Causes and effects

Caused by

70,000 Ervebo doses, 20,000 as a trial

The 70,000 Ervebo doses released on 20 August supplied the frontline vaccinations and the planned trial.

Occurred 19 Aug 2026

Read story →

Ebola shifts south to DR Congo's Butembo

The trial is to start in Ituri while new cases have moved to North Kivu.

Occurred 23 Sept 2026

Read story →

This Event

WHO: 2,000 Congolese workers get Ervebo

The Phase 3 ring trial is the most rigorous planned test of whether Ervebo protects anyone against Bundibugyo, and it needs fresh cases where it starts. A separate MSF study of frontline workers began on 19 September.

Different Perspectives

IGWG co-chair Tovar da Silva Nunes

The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.

Fraport

The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.

European Centre for Disease Prevention and Control

ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.

Pan American Health Organization

PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.

Bangladesh Directorate General of Health Services

The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.

Minapharm

The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.